EUVIMEDEUVIMED entdecken
FallberichtVergleichsstudieOpen Access

Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss

Muhammad Haseeb, Jagpreet Chhatwal, Jade Xiao, Pichamol Jirapinyo, Christopher C Thompson

JAMA Network Open · 12.04.2024 · 7 (4) · e246221

DOI: 10.1001/jamanetworkopen.2024.6221 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JAMA Network Open, online erschienen am 12.04.2024. Verfasst von Muhammad Haseeb und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Gastroplasty, Glucagon-Like Peptides. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Obesity is a disease with a large socioeconomic burden. Endoscopic sleeve gastroplasty (ESG) is a minimally invasive endoscopic bariatric procedure with wide global adoption. More recently, new weight-loss medications, such as glucagon-like peptide-1 receptor agonists (eg, semaglutide), have attracted increased attention due to their efficacy. However, their cost-effectiveness over an extended period compared with ESG is a critical gap that needs to be better explored for informed health care decision-making.

Objective

To assess the cost-effectiveness of semaglutide compared with ESG over 5 years for individuals with class II obesity. Design, Setting, and Participants This economic evaluation study, conducted from September 1, 2022, to May 31, 2023, used a Markov cohort model to compare ESG and semaglutide, with a no-treatment baseline strategy. The study comprised adult patients in the US health care system with class II obesity (body mass index [BMI] of 35-39.9). The base case was a 45-year-old patient with class II obesity (BMI of 37). Patients undergoing ESG were subjected to risks of perioperative mortality and adverse events with resultant costs and decrement in quality of life.

Interventions

Strategies included treatment with semaglutide and ESG. Main Outcomes and Measures Costs (2022 US dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) with a willingness-to-pay threshold of $100 000/QALY. A 5-year time horizon with a cycle length of 1 month with a 3% discount rate was used. Probabilities, costs, and quality-of-life estimates of the model were derived from published literature. One-way, 2-way, and probabilistic sensitivity analyses were also performed.

Results

The model found that ESG was more cost-effective than semaglutide over a 5-year time horizon, with an ICER of –$595 532/QALY. Endoscopic sleeve gastroplasty added 0.06 QALYs and reduced total cost by $33 583 relative to semaglutide. The results remained robust on 1-way and probabilistic sensitivity analyses. Endoscopic sleeve gastroplasty sustained greater weight loss over 5 years vs semaglutide (BMI of 31.7 vs 33.0). To achieve nondominance, the annual price of semaglutide, currently $13 618, would need to be $3591. Conclusions and Relevance This study suggests that ESG is cost saving compared with semaglutide in the treatment of class II obesity. On price threshold analyses, a 3-fold decrease in the price of semaglutide is needed to achieve nondominance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GastroplastyGlucagon-Like PeptidesAdultHumansMiddle AgedObesityQuality of LifeWeight LossSemaglutide

Substanzen

Glucagon-Like PeptidesSemaglutide

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts.
  • Department of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Institute for Technology Assessment, Massachusetts General Hospital, Boston.
  • Georgia Institute of Technology, Atlanta.

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Haseeb, M., Chhatwal, J., Xiao, J., Jirapinyo, P., & Thompson, C. C. (2024). Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss. JAMA Network Open, 7(4), e246221. https://doi.org/10.1001/jamanetworkopen.2024.6221

Vancouver

Haseeb M, Chhatwal J, Xiao J, Jirapinyo P, Thompson CC. Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss. JAMA Network Open. 2024;7(4):e246221. doi:10.1001/jamanetworkopen.2024.6221

BibTeX
@article{Haseeb2024,
  author = {Haseeb, Muhammad and Chhatwal, Jagpreet and Xiao, Jade and Jirapinyo, Pichamol and Thompson, Christopher C},
  title = {Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {4},
  pages = {e246221},
  doi = {10.1001/jamanetworkopen.2024.6221}
}
Kostenlos starten →